SUBCUTANEOUSLY ADMINISTERED BISPECIFIC ANTIBODIES FOR USE IN THE TREATMENT OF CANCER
First Claim
Patent Images
1. A method for the treatment of a cancer disease, said method comprising administering a bispecific antibody via the subcutaneous route.
3 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to the use of T cell redirecting, bispecific, in particular trifunctional, antibodies for the treatment of a cancer disease, wherein said antibody is administered via the subcutaneous route. Thereby, the release of proinflammatory cytokines is reduced and, simultaneously, the release of inhibitory cytokines is substantially suppressed. That treatment by bispecific, in particular trifunctional, antibodies may be combined in a combination therapy with other anti-cancer drugs.
22 Citations
40 Claims
- 1. A method for the treatment of a cancer disease, said method comprising administering a bispecific antibody via the subcutaneous route.
-
7. (canceled)
-
11. (canceled)
-
14. (canceled)
-
15. (canceled)
-
17. (canceled)
-
19. (canceled)
-
23. (canceled)
-
24. (canceled)
-
27. (canceled)
-
28. (canceled)
- 29. A method for the treatment of a cancer disease comprising administering a pharmaceutical composition, wherein said pharmaceutical composition comprises a bispecific, in particular a T cell redirecting, trifunctional, antibody, wherein said composition is administered subcutaneously.
-
30. (canceled)
-
37. (canceled)
-
38. (canceled)
-
40. (canceled)
Specification